What is VP4896 used for?

VP4896 is indicated for Type 2 diabetes.

VP4896 is developed by Voyager Pharmaceutical Corporation.

What are the side effects of VP4896?

Common side effects include Increased risk of diabetic ketoacidosis.

Last reviewed 2026-05-13 · How we verify

VP4896

Voyager Pharmaceutical Corporation · Phase 3 active Small molecule

VP4896 is a small molecule that targets the SGLT2 receptor.

VP4896 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.

At a glance

Generic name	VP4896
Sponsor	Voyager Pharmaceutical Corporation
Drug class	SGLT2 inhibitor
Target	SGLT2
Modality	Small molecule
Therapeutic area	Diabetes
Phase	Phase 3

Mechanism of action

By inhibiting SGLT2, VP4896 reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, such as canagliflozin and empagliflozin.

Approved indications

Type 2 diabetes

Common side effects

Increased risk of diabetic ketoacidosis

Key clinical trials

ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VP4896 CI brief — competitive landscape report
VP4896 updates RSS · CI watch RSS
Voyager Pharmaceutical Corporation portfolio CI